Cardiac Surgery News and Research

RSS

Two-thirds of public hospitals are in rural areas

Two-thirds of the nation's 1,131 public hospitals were in rural areas in 2008, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

18 Sep 2010

Integra LifeSciences launches new line of Ruggles kerrison rongeurs for neuro and spine surgeries

Integra LifeSciences Holdings Corporation announced the introduction of a new line of extended length and "detachable" Ruggles™kerrison rongeurs, which are key instruments used in a variety of neuro and spine surgeries.

15 Sep 2010

Perceval S Aortic Heart Valve early clinical results to be presented at 24th EACTS

Sorin Group, a global medical company and a leader in the treatment of cardiovascular diseases, announced today the presentation by Francois Laborde, MD, Professor of Cardiac Surgery, Institut Mutualiste Montsouris, Paris, France at the 24th EACTS Annual Meeting in Geneva, Switzerland of the early clinical results of the first 180 patients implanted with the Perceval S Aortic Heart Valve (investigational device).

15 Sep 2010

Convergent Procedure for AF highlighted at EACTS 2010

The Convergent Procedure, a novel approach to treat atrial fibrillation (AF), enabled by epicardial ablation products from nContact Surgical, Inc., was highlighted at the Techno-College Atrial Fibrillation Session of the EACTS (European Association for Cardio-Thoracic Surgery) Annual Meeting in Geneva, Switzerland. More than 1,000 medical professionals attended the 2010 Techno-College Programme to receive an update on the latest technical advancements in cardiothoracic surgery.

14 Sep 2010

FDA approves CorMatrix ECM for Pericardial Closure

CorMatrix Cardiovascular, Inc., a medical device company developing and delivering unique extracellular matrix (ECM) biomaterial devices that harness the body's innate ability to repair damaged cardiovascular tissue, announced today that FDA has granted conditional approval for the start of a multi-center, prospective, randomized clinical trial to demonstrate the safety and efficacy of the CorMatrix ECM for Pericardial Closure to reduce the incidence of new onset postoperative atrial fibrillation.

13 Sep 2010

BRINAVESS IV granted marketing approval in EU for conversion of recent onset AF to sinus rhythm

MSD and Cardiome Pharma Corp. today announced that the intravenous (IV) formulation of BRINAVESS™ (vernakalant) has been granted marketing approval in the European Union (EU), Iceland and Norway for the conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults.

2 Sep 2010

International Symposium to explore Hybrid approach for congenital heart disease

Interventional cardiologists and cardiothoracic surgeons throughout the United States and the world, who treat patients with congenital heart disease, will gather at the Hilton Columbus at Easton Town Center August 31-September 2, 2010 for the International Symposium on the Hybrid Approach to Congenital Heart Disease (ISHAC).

31 Aug 2010

Data suggests BIMA improves coronary artery bypass graft efficiency

Recent trial data indicate that coronary artery bypass graft (CABG) surgery remains the most effective intervention for patients with severe coronary artery disease (CAD).

31 Aug 2010

Salinas Valley Memorial participates in trial of AngelMed Guardian System in high-risk heart patients

Imagine a day when you could be alerted to your impending heart attack before it happens. Research that got underway today at Salinas Valley Memorial Healthcare System could help that become a reality someday.

26 Aug 2010

Getinge's vascular graft production unit receives warning letter from FDA

Getinge's production unit in Wayne, New Jersey, US, has received a warning letter from the US FDA (Food and Drug Administration). The warning letter originates from an inspection performed by the authority on the Wayne plant during the spring of 2010. The FDA's observations and remarks relate to the manufacture of vascular grafts

23 Aug 2010

Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug

Silence Therapeutics plc, a leading international RNAi therapeutics company, is pleased to note that its partner, Quark Pharmaceuticals, Inc., has announced the grant of an option to Novartis to obtain an exclusive worldwide license to develop and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates Silence's AtuRNAi technology.

20 Aug 2010

Two-day LEAN training course for healthcare professionals

The two-day course is a didactic and hands-on introduction to LEAN management philosophy and manufacturing-based work rules and tools designed to prepare physicians, administrators, and technical support staff for the realities and potential successes of practicing in a LEAN environment. The sessions are not only oriented to laboratory medicine but also adapted to the processes encountered in clinical services as well.

19 Aug 2010

Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.

18 Aug 2010

Study deems gentamicin-collagen sponge ineffective in reducing sternal wound infections

Contradicting previous study results, insertion of a sponge that contains the antibiotic gentamicin at the time of surgical closure following cardiac surgery did not reduce the rate of sternal wound infections after 3 months, compared to patients who did not receive the intervention, according to a study in the August 18 issue of JAMA.

18 Aug 2010

Integra LifeSciences signs 3-year contract for JARIT surgical instruments with Amerinet GPO

Integra LifeSciences Holdings Corporation announced today that it signed a three-year contract for JARIT® surgical instruments with Amerinet, a leading national healthcare group purchasing organization.

12 Aug 2010

Bluhm Cardiovascular Institute implants two Heartware ventricular assist devices

The Bluhm Cardiovascular Institute of Northwestern Memorial Hospital recently implanted a patient with two of the smallest experimental ventricular assist devices (VADs) currently available for study in humans. VADs are designed to assist either the right (RVAD) or left (LVAD) ventricle, or both (BiVAD) at once. This is the first time that two Heartware VADs have been implanted in the left and right ventricles anywhere in North America—a "game changer" in the realm of heart assist devices according to Patrick M. McCarthy, MD, chief of the hospital's division of cardiac surgery and director of the hospital's Bluhm Cardiovascular Institute.

11 Aug 2010

Stanford Hospital & Clinics establishes Kidney and Pancreas Transplant Clinic at Salinas Valley Memorial

The partnership between Salinas Valley Memorial Healthcare System and Stanford Hospital & Clinics has added another facet of care, bringing world-class organ transplant care to patients on the Central Coast. Stanford's Adult Kidney and Pancreas Transplant Program will begin seeing patients at Salinas Valley Memorial's Ryan Ranch facility.

11 Aug 2010

Higher case volume associated with better outcomes of cardiac surgery: Study

A new analysis led by researchers at UCSF shows that avoiding lowest-volume hospitals and maximizing adherence to quality care processes are both effective approaches to reducing costs associated with coronary bypass surgery.

30 Jul 2010

Dyax second-quarter total revenues increase to $15.1 million

Dyax Corp. today announced financial results for the second quarter ended June 30, 2010.

28 Jul 2010

MAQUET Cardiovascular launches VASOVIEW HEMOPRO 2 Endoscopic Vessel Harvesting System

MAQUET Cardiovascular today announced the launch of its VASOVIEW HEMOPRO 2 Endoscopic Vessel Harvesting (EVH) System, which utilizes next-generation HEMOPRO cut-and-seal technology to reduce thermal spread and to achieve optimal conduit quality for coronary artery bypass graft (CABG) surgery patients. The minimally invasive VASOVIEW HEMOPRO 2 system is an example of MAQUET Cardiovascular's commitment to EVH, and technologies that promote the highest level of conduit quality.

27 Jul 2010